Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Alterity Therapeutics Investor Presentation

April 10, 2019 Kerry Rowe

Alterity Therapeutics Investor Presentation 10 April 2019

Post navigation

Alterity Therapeutics Launches to Asian Investors

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Related Posts

Prana Provides Update on PBT2 Alzheimer’s Disease Extension trial

December 12, 2013

Prana Biotechnology 2014 Annual Report

October 1, 2014

Prana Announces Successful Phase 2 Results in Huntington Disease Trial

February 18, 2014

Recent Posts

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065